Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Keech

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
The Lancet. Diabetes & Endocrinology|August 2, 2016
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials, William Herrington, Jonathan Emberson, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Journal of Clinical Epidemiology|May 4, 2019
Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
American Heart Journal|May 28, 2018
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trialErin A Bohula, Benjamin M Scirica, Christina Fanola, et al.
Journal of the American College of Cardiology|February 7, 2024
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary DiseaseDaniel J McClintick, Michelle L O'Donoghue, Gaetano M De Ferrari, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
The Lancet. Child & Adolescent Health|December 13, 2021
Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trialKristy P Robledo, William O Tarnow-Mordi, Ingrid Rieger, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
The Lancet. Diabetes & Endocrinology|August 2, 2016
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials, William Herrington, Jonathan Emberson, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Journal of Clinical Epidemiology|May 4, 2019
Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
American Heart Journal|May 28, 2018
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trialErin A Bohula, Benjamin M Scirica, Christina Fanola, et al.
Journal of the American College of Cardiology|February 7, 2024
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary DiseaseDaniel J McClintick, Michelle L O'Donoghue, Gaetano M De Ferrari, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
The Lancet. Child & Adolescent Health|December 13, 2021
Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trialKristy P Robledo, William O Tarnow-Mordi, Ingrid Rieger, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Pageof 10